Entrada Therapeutics
TRDA
107 hedge funds and large institutions have $210M invested in Entrada Therapeutics in 2025 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 45 increasing their positions, 23 reducing their positions, and 26 closing their positions.
96% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 23
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
2.53% less ownership
Funds ownership: 85.06% → 82.53% (-2.5%)
4% less funds holding
Funds holding: 111 → 107 (-4)
15% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 26
27% less capital invested
Capital invested by funds: $290M → $210M (-$79.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Royce & Associates
New York
|
+$1.8M |
| 2 |
Millennium Management
New York
|
+$1.37M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$875K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$779K |
| 5 |
Morgan Stanley
New York
|
+$720K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.98M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$4.83M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.36M |
| 4 |
5VM
5AM Venture Management
San Francisco,
California
|
-$805K |
| 5 |
Lazard Asset Management
New York
|
-$309K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CA
126
CoreCap Advisors
Southfield,
Michigan
| – | -$434 | -48 | Closed |
|
|
PFBT
127
Parkside Financial Bank & Trust
Saint Louis,
Missouri
| – | -$362 | -40 | Closed |
|
|
FFO
128
Fortitude Family Office
Scottsdale,
Arizona
| – | -$334 | -37 | Closed |
|
|
CCM
129
Coldstream Capital Management
Bellevue,
Washington
| – | -$298 | -33 | Closed |
|
|
CMBA
130
C.M. Bidwell & Associates
Honolulu,
Hawaii
| – | -$262 | -29 | Closed |
|
|
RIL
131
Rothschild Investment LLC
Chicago,
Illinois
| – | -$181 | -20 | Closed |
|
132
Amundi
Paris,
France
| – | -$96 | -12 | Closed |
|
|
SS
133
SBI Securities
Tokyo,
Japan
| – | -$9 | -1 | Closed |
|
TRDA Hedge Fund Activity: Q2 2025 in Review
107 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q2 2025, worth a combined $210M — down 27% from $290M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of TRDA and 22 opened new positions — a net loss of 4 holders — while 23 trimmed existing stakes and 45 added.
The largest buyer was Royce & Associates, opening a new position worth an estimated $1.8M. The largest seller was Fidelity Investments, cutting an estimated $5.98M.
- 107 institutional investors held Entrada Therapeutics (TRDA) as of Q2 2025, down from 111 in Q1 2025.
- Funds reported $210M of Entrada Therapeutics stock for Q2 2025, down 27% quarter-over-quarter.
- 22 funds opened new Entrada Therapeutics positions in Q2 2025 and 26 closed out, a net change of -4 holders.
- The largest Entrada Therapeutics buyer in Q2 2025 was Royce & Associates, an estimated $1.8M added.
- The largest Entrada Therapeutics seller in Q2 2025 was Fidelity Investments, an estimated $5.98M sold.
Based on aggregated 13F filings for Q2 2025.